Russian Journal of Skin and Venereal DiseasesRussian Journal of Skin and Venereal DiseasesРоссийский журнал кожных и венерических болезней1560-95882412-9097Eco-Vector3675710.17816/dv36757ArticlesСтатьиResearch ArticleADALIMUMAB IN PSORIASIS: OUR FIRST EXPERIENCEНаш первый опыт применения адалимумаба при псориазеKocherginN. GКочергинН. Г.

д-р мед. наук, проф.

nkocha@yandex.ruPotekayevN. NПотекаевН. Н.

д-р мед. наук, проф.

SmirnovaL. MСмирноваЛ. М.

канд. мед. наук

SerovD. NСеровД. Н.

науч. сотр.

OlisovaO. YuОлисоваО. Ю.

д-р мед. наук, проф.

BabushkinA. MБабушкинА. М

аспирант

ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава РоссииМосковский научно-практический центр дерматовенерологии и косметологииХанты-Мансийский клинический кожно-венерологический диспансер15102012155NO5 (2012)№5 (2012)374121072020Copyright ©; 2012, Eco-VectorCopyright ©; 2012, ООО "Эко-Вектор"2012Eco-VectorООО "Эко-Вектор"https://rjsvd.com/1560-9588/article/view/36757

Severe refractory psoriasis is often a difficult therapeutic problem. Classical total systems antipsoriatic therapeutic protocols are now supplemented by modern high-technological highly effective biological preparations. Basic data on anticytokine drugs are presented. The results of the first use of adalimumab (the first Russian drug) have demonstrated its high clinical efficiency: dynamic reduction of the psoriasis activity and dissemination index (PASI) and of dermatological quality of life index, good compliancy and convenient use in an outpatient setting.

Тяжелый рефрактерный псориаз нередко представляет собой трудно решаемую терапевтическую задачу. Классические виды системной антипсориатической терапии сегодня дополняются современными высокотехнологичными и высокоэффективными биологическими препаратами. Представлены основные сведения об антицитокиновых препаратах, и на примере первого российского опыта применения адалимумаба продемонстрирован его высокий клинический эффект с динамичной редукцией индекса активности и распространенности поражения при псориазе (PASI) и дерматологического индекса качества жизни (ДИКЖ), отличной комплаентностью и удобством использования в амбулаторной дерматологической практике.

PASIpsoriasisantipsoriatic therapyadalimumabPASIdermatological quality of life indexпсориазантипсориатическая терапияадалимумабдерматологический индекс качества жизниDubertret L., Mrowietz U., Ranki A., van de Kerkhof P.C., Chimenti S., Lotti T., Schäfer G.; EUROPSO Patient Survey Group. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br. J. Dermatol. 2006; 155(4): 729—36.Winterfield L.S., Menter A., Gordon K., Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann. Rheum. Dis. 2005; 64(suppl. 2): ii87—90.Mrowietz U., Kragballe K., Nast A., Reich K. Strategies for improving the quality of care in psoriasis with the use of treatment goals-a report on an implementation meeting. J. Eur. Acad. Dermatol. Venereol. 2011; 25(suppl. 3): 1—13. doi: 10.1111/j.1468-3083.2011.04033.x.Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp. Dermatol. 2011; 20(4): 303—7. doi: 10.1111/j.1600-0625.2011.01261.x.Love T.J., Qureshi A.A., Karlson E.W., Gelfand J.M., Choi H.K., et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003—2006. Arch. Dermatol. 2011; 147(4): 419—24.Reich K., Langley R.G., Lebwohl M., Szapary P., Guzzo C., Yeilding N., et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br. J. Dermatol. 2011; 164(4): 862—72. doi: 10.1111/j.1365-2133.2011.10257.x.Cargill M., Schrodi S., Chang M., Garcia V.E., Brandon R., Callis K.P., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 2007; 80(2): 273—90.Nechansky A., Kircheis R. Immunogenicity of therapeutics: a matter of efficacy and safety. Expert Opin. Drug Discov. 2010; 5(11): 1067—79.Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B, et al.; American Academy of Dermatology Work Group. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.J. Am. Acad. Dermatol. 2011; 65(1): 137—74.Papp K., Gulliver W., Lynde C., Poulin Y., Ashkenas J.; Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. J. Cutan. Med. Surg. 2011; 15(4): 210—9.Smith C.H., Anstey A.V., Barker J.N., Burden A.D., Chalmers R.J., Chandler D.A., et al.; Chair of Guideline Group. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br. J. Dermatol. 2009; 161(5): 987—1019.Menter A., Tyring S.K., Gordon K.B., Kimball A.B., Leonardi C.L., Langley R.G., et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J. Am. Acad. Dermatol. 2008; 58(1): 106—15.Revicki D.A., Willian M.K., Menter A., Gordon K.B., Kimball A.B., Leonardi C.L., et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J. Dermatol. Treat. 2007; 18(6): 341—50.Saurat J.H., Stingl G., Dubertret L., Papp K., Langley R.G., Ortonne J.P., et al.; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol. 2008; 158(3): 558—66.Burmester G.R., Mease P., Dijkmans B.A., Gordon K., Lovell D., Panaccione R., et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann. Rheum. Dis. 2009; 68(12): 1863—9.doi: 10.1136/ ard.2008.102103.Van den Bosch F., Manger B., Goupille P., McHugh N., Rodevand E., Holck P., et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann. Rheum. Dis. 2010; 69(2): 394—9.Ortonne J.P., Chimenti S., Reich K., Gniadecki R., Sprngel P., Unnebrink K., et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J. Eur. Acad. Dermatol. Venereol. 2011; 25(9): 1012—20. doi: 10.1111/j.1468-3083.2010.03944.x.Gordon K., Papp K., Poulin Y., Gu Y., Rozzo S., Sasso E.H. Longterm efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J. Am. Acad. Dermatol. 2012; 66(2): 241—51.